A straightforward method to quantify circulating mRNAs as biomarkers of colorectal cancer.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
15 02 2023
15 02 2023
Historique:
received:
20
06
2022
accepted:
13
02
2023
entrez:
15
2
2023
pubmed:
16
2
2023
medline:
18
2
2023
Statut:
epublish
Résumé
Optimizing the biomarker combination to be analyzed in liquid biopsies should improve personalized medicine. We developed a method to purify circulating cell-free mRNAs from plasma samples and to quantify them by RT-qPCR. We selected three candidate colorectal cancer biomarkers (B2M, TIMP-1, and CLU). Their mRNA levels were significantly higher in plasma of patients with metastatic colorectal cancer patients (mCRC) (n = 107) than in healthy individuals (HI) (n = 53). To increase the discriminating performance of our method, we analyzed the sum of the three mRNA levels (BTC index). The area under the ROC curve (AUC) to estimate the BTC index capacity to discriminate between mCRC and HI plasma was 0.903. We also determined the optimal BTC index cut-off to distinguish between plasma samples, with 82% of sensitivity and 93% of specificity. By using mRNA as a novel liquid biopsy analytical parameter, our method has the potential to facilitate rapid screening of CRCm.
Identifiants
pubmed: 36792801
doi: 10.1038/s41598-023-29948-4
pii: 10.1038/s41598-023-29948-4
pmc: PMC9932139
doi:
Substances chimiques
RNA, Messenger
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2739Informations de copyright
© 2023. The Author(s).
Références
Cell Mol Life Sci. 2018 Jan;75(2):323-334
pubmed: 28849249
Mol Oncol. 2020 May;14(5):1001-1015
pubmed: 32246814
Cancers (Basel). 2019 Mar 30;11(4):
pubmed: 30935089
Annu Rev Immunol. 1989;7:601-24
pubmed: 2469442
Cell. 2010 Apr 2;141(1):52-67
pubmed: 20371345
Int J Biol Markers. 2019 Sep;34(3):292-301
pubmed: 31578137
Clin Exp Gastroenterol. 2020 Aug 13;13:273-284
pubmed: 32884322
Cancer Epidemiol Biomarkers Prev. 2016 Apr;25(4):657-64
pubmed: 26908438
Clin Biochem. 2020 Jan;75:62-69
pubmed: 31672651
J Exp Clin Cancer Res. 2016 Sep 20;35(1):148
pubmed: 27644693
Cancer Cell. 2015 Nov 9;28(5):666-676
pubmed: 26525104
Int J Cancer. 2012 Aug 15;131(4):855-63
pubmed: 21953582
Nat Rev Cancer. 2017 Apr;17(4):223-238
pubmed: 28233803
Blood. 2021 Jun 10;137(23):3181-3191
pubmed: 33940602
Clin Cancer Res. 1999 Aug;5(8):1961-5
pubmed: 10473072
Nat Med. 2014 Apr;20(4):430-5
pubmed: 24658074
Breast Cancer Res Treat. 2009 Sep;117(1):31-44
pubmed: 18787947
Int J Biochem Cell Biol. 2002 Nov;34(11):1430-48
pubmed: 12200037
Blood. 2019 May 30;133(22):2359-2364
pubmed: 30833413
Cancer Invest. 2012 Jan;30(1):72-8
pubmed: 22236192
PeerJ. 2021 Feb 16;9:e10859
pubmed: 33628641
Mol Cancer Res. 2014 Sep;12(9):1324-33
pubmed: 24895412
Nat Commun. 2021 Apr 21;12(1):2357
pubmed: 33883548
Cancer Res. 2005 Feb 1;65(3):898-906
pubmed: 15705888